越南学名药市场评估：依应用、类型、品牌、给药途径、通路、地区、机会、预测（2017-2031）

越南学名药市场规模预计将从2023年的39亿美元增至2031年的74.2亿美元，2024-2031年预测期间年复合成长率为 8.39%。政府采取越来越多的措施来支持市场成长，以提高人们对学名药及其有效性的各种好处、专利到期以及该国非传染性疾病威胁日益增加的认识。此外，政府鼓励外国公司投资的支持措施和药品法的推出也支持了市场成长。2024年1月，越南卫生部宣布修订该国药品法，给予外国公司更多诱因和权利。该修正案扩大了投资诱因范围，将越南的学名药和高科技药物製造纳入其中。它还包括控制和预防社会疾病所需的药品、生物技术产品、生物製品和疫苗。新规定也鼓励外商投资、技术转移以及学名药和原料药的研究和生产。

越南多种慢性病的流行增加了对平价药品的需求，扩大了越南学名药市场的规模。

根据世界卫生组织（WHO）估计，越南每年约有 115,000 人死于癌症，新诊断癌症人数为 165,000 人。为了对抗这些疾病和病症，并促进学名药在国内的使用，政府提供了各种激励措施来支持製药业的发展和扩张以及高品质学名药和创新药物的生产。这些努力支持市场扩张。

此外，该国医疗保健行业的快速扩张、基础设施发展投资的增加、确保基本药物的获取以及促进学名药的公众教育也支持了市场的成长。

新法规支持市场扩张

该国卫生部对药品包装和标籤进行了新的修订，并于2024年 1月 15 日生效。修订内容包括将二维码、条码等整合到标籤中，符合卫生部将标籤和说明书数位化、确保药品效率、支持可追溯性等目标。该法规还要求定期更新，以确保学名药符合品牌药的品质和标准。这些法规目的是增强公众对学名药的信心，并透过提高品质和确保合规性来支持市场扩张。

非传染性疾病增加推动市场需求

越南糖尿病、癌症、呼吸系统疾病、心血管疾病等非传染性疾病患者数量不断增加，带动了越南学名药市场的需求。根据2022年 9月发表在 PLOS ONE 上的一篇论文，非传染性疾病是越南的主要原因之一，其中癌症、糖尿病和心血管疾病是最常见的。该国非传染性疾病负担的增加可归因于城市化进程的加速和经济成长。此外，由于地理障碍和社会经济地位低下，生活在越南山区的人们获得卫生服务的机会有限，因此更容易罹患非传染性疾病。因此，非传染性疾病的威胁日益增加，国内对学名药的需求不断增加。

大公司与医院之间的合作支持市场成长

市场参与者和医院之间加强合作以提高慢性病患者的护理品质，预计将对未来几年的市场成长产生积极影响。2024年 6月，Vietnam National Cancer Hospital和Sandoz集团签署了一份谅解备忘录，以提高河内和整个越南癌症患者的照护标准。Sandoz努力改善患者获得负担得起的药物的机会，包括抗感染药物和癌症治疗等领域的生物相似药和学名药。此外，该公司于2024年 3月与Ho Chi Minh City Oncology Hospital建立了类似的合作关係。这些伙伴关係预计将促进慢性病患者获得学名药。

本报告研究和分析越南学名药市场，提供市场规模和预测、市场动态以及主要公司的状况。

目录

第1章 专案范围与定义

第2章 研究方法

第3章 执行摘要

第4章 越南学名药市场展望（2017-2031）

• 市场规模分析与预测
  • 金额
  • 数量
• 市占率分析与预测
  • 依用途
  • 依类型
  • 依品牌
  • 依给药途径
  • 依通路
  • 依地区
  • 市占率分析：依公司划分（金额）（前 5 名公司及其他 -2023年）
• 市场地图分析（2023年）
  • 依用途
  • 依类型
  • 依品牌
  • 依给药途径
  • 依通路
  • 依地区

第5章 供需分析

第6章 进出口分析

第7章 价值链分析

第8章 波特五力分析

第9章 PESTLE分析

第10章 价格分析

第11章 市场动态

• 市场驱动因素
• 市场挑战

第12章 市场趋势与发展

第13章 监理架构与创新

• 生物利用度/生物等效性测试
• 监理机关的核准

第14章 专利到期

第15章 个案研究

第16章 竞争态势

• 前 5 名市场领导者的竞争矩阵
• 前 5 名的公司的SWOT 分析
• 前10名主要企业状况
  • DHG Pharmaceutical Joint-Stock Company
  • Sanofi-Aventis Vietnam Company Limited
  • Imexpharm Corporation
  • TRAPHACO JOINT STOCK COMPANY
  • BIDIPHAR
  • STADA Arzneimittel AG
  • Sandoz Group AG

第17章 策略建议

第18章 关于本公司，免责声明

Vietnam generic drugs market is projected to witness a CAGR of 8.39% during the forecast period 2024-2031, growing from USD 3.90 billion in 2023 to USD 7.42 billion in 2031. The market's growth is supported by the government's rising measures to increase awareness about the various advantages associated with generics and their efficacy, the expiration of patents, and the growing threat of non-communicable diseases in the country. The market's growth is also supported by supportive government measures and the introduction of pharmacy laws to boost investments by foreign companies. In January 2024, the Ministry of Health in Vietnam released an amendment to the country's Pharmacy Law to give foreign companies more incentives and rights. With the amendment, the scope of investment incentives has been expanded to include generic specialty drugs, and high-tech drug manufacturing in Vietnam. It also includes drugs necessary for controlling and preventing social diseases, biotechnological products, biological products, and vaccines. The new clause also encourages foreign investments, technology transfer, and research and production of generic specialty drugs and pharmaceutical raw materials, among others.

Due to the increasing prevalence of several chronic conditions in the country, the demand for affordable medications is rising, boosting the Vietnam generic drugs market size.

According to the estimates of the World Health Organization (WHO), approximately 115,000 new deaths related to cancer and 165,000 new cases of cancer are recorded every year in Vietnam. To propel the availability of generics in the country to combat such diseases and disorders, the government has introduced various preferential policies to support the development and expansion of the pharmaceutical industry and the production of high-quality generics and innovative drugs. Such efforts are supporting the market's expansion.

Furthermore, the rapid expansion of the country's healthcare sector, increasing investments towards infrastructural development, ensuring the accessibility of required medications, and promoting education among the general population about generics are also supporting the market's growth.

New Regulations Support Market Expansion

The country's Ministry of Health introduced new amendments regarding the packaging and labeling of pharmaceutical products that went into effect on January 15, 2024. The amendments include the integration of QR codes and barcodes, among others, into the labels, aligning with the Ministry of Health's goal for electronic labeling and instructions, ensuring the efficiency of pharmaceutical products, and supporting their traceability. The regulations also require regular updates on generics to ensure that they are in alignment with the quality and standards of the original brand-name drugs. These regulations aim to improve the quality of generic drugs and ensure compliance, enhancing the population's confidence in generic drugs and supporting the market's expansion.

Rising Cases of Non-Communicable Diseases Boost Market Demand

The increasing cases of non-communicable diseases, including diabetes, cancer, respiratory diseases, and cardiovascular diseases in Vietnam, are bolstering the Vietnam generic drugs market demand. According to an article published in PLOS ONE in September 2022, non-communicable diseases are one of the leading causes of death in Vietnam, with cancer, diabetes, and cardiovascular disease being the most common. The growing burden of non-communicable diseases in the country can be attributed to increasing urbanization and economic growth. Furthermore, the individuals living in the mountainous region of the country are more vulnerable to non-communicable diseases due to limited access to healthcare services because of geographical barriers and low socioeconomic status. The increasing threat of non-communicable diseases is thus bolstering the requirement for generic drugs in the country.

Collaborations Between Key Players and Hospitals Support Market Growth

The rising collaborations between the key players of the market and hospitals to improve the quality of care for patients battling chronic conditions are expected to influence the market's growth in the coming years positively. In June 2024, Vietnam National Cancer Hospital and Sandoz Group AG signed a Memorandum of Understanding (MoU) to improve the standard of care for patients suffering from cancer in Hanoi and around the country. Sandoz is committed to improving patient access to affordable medications, including biosimilars and generics, in the field of anti-infectives and oncology, among others. Additionally, the company entered a similar partnership with Ho Chi Minh City Oncology Hospital in March 2024. Such collaborations are expected to boost the availability of generics for patients with chronic conditions.

Biosimilars Hold Significant Market Share

The growth of the segment can be attributed to the increasing preference for lower-cost alternatives due to the rising costs of prescription drugs in Vietnam. The increasing introduction of biosimilars also supports the growth of the Vietnam generic drugs market. In March 2022, Shanghai Henlius Biotech, Inc. collaborated with Getz Pharma Limited to commercialize Handayuan, an adalimumab biosimilar, across several countries in Africa and Asia. The supply and licensing agreement will allow the latter to market the biosimilar in Vietnam, Ukraine, Sri Lanka, Myanmar, Cambodia, Philippines, and Uzbekistan, among others. Such agreements and collaborations are expected to boost the accessibility of biosimilars in Vietnam, supporting the segment's expansion and growth of the Vietnam generic drugs market.

Future Market Scenario (2024-2031F)

As per the Vietnam generic drugs market analysis, the market is expected to witness significant growth in the coming years owing to rising investments in pharmaceutical manufacturing, the growing prevalence of chronic diseases, and increasing government initiatives to bolster the utilization of generics. Additionally, as the market expansion continues, it is expected to provide lucrative growth opportunities for both international and domestic pharmaceutical companies. The increasing measures by the government to ensure the availability of affordable medications are also expected to propel the demand for generic drugs in Vietnam.

Key Players Landscape and Outlook

The increasing investments by the leading market players in modern medicines are supporting the market's expansion. In April 2024, TRAPHACO JOINT STOCK COMPANY announced that they would focus on enhancing their research and development capabilities as well as new technology products and launch their first generic drugs. To facilitate these goals, the company is recruiting external research and development experts and increasing its investments toward enhancing its workforce and internal departments. Such investments are expected to boost the manufacture of generic drugs in Vietnam and provide lucrative growth opportunities to the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Vietnam Generic Drugs Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Application
    • 4.2.1.1. Neurovascular
    • 4.2.1.2. Cardiovascular
    • 4.2.1.3. Dermatology
    • 4.2.1.4. Oncology
    • 4.2.1.5. Diabetology
    • 4.2.1.6. Respiratory
    • 4.2.1.7. Others
  • 4.2.2. By Type
    • 4.2.2.1. Biosimilar Generics
    • 4.2.2.2. Small Molecule Generics
  • 4.2.3. By Brand
    • 4.2.3.1. Branded Generic
    • 4.2.3.2. Pure Generic
  • 4.2.4. By Route of Administration
    • 4.2.4.1. Oral
    • 4.2.4.2. Injectable
    • 4.2.4.3. Topical
    • 4.2.4.4. Others
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacy
    • 4.2.5.2. Retail Pharmacy
    • 4.2.5.3. Online Pharmacy
  • 4.2.6. By Region
    • 4.2.6.1. North
    • 4.2.6.2. South
    • 4.2.6.3. Central
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Application
  • 4.3.2. By Type
  • 4.3.3. By Brand
  • 4.3.4. By Route of Administration
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Bioavailability/Bioequivalence Studies
• 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. DHG Pharmaceutical Joint-Stock Company
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Sanofi-Aventis Vietnam Company Limited
  • 16.3.3. Imexpharm Corporation
  • 16.3.4. TRAPHACO JOINT STOCK COMPANY
  • 16.3.5. BIDIPHAR
  • 16.3.6. STADA Arzneimittel AG
  • 16.3.7. Sandoz Group AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Vietnam Generic Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Vietnam Generic Drugs Market, By Volume, In Number of Prescriptions, 2017-2031F
• Figure 3. Vietnam Generic Drugs Market Share (%), By Application, 2017-2031F
• Figure 4. Vietnam Generic Drugs Market Share (%), By Type, 2017-2031F
• Figure 5. Vietnam Generic Drugs Market Share (%), By Brand, 2017-2031F
• Figure 6. Vietnam Generic Drugs Market Share (%), By Route of Administration, 2017-2031F
• Figure 7. Vietnam Generic Drugs Market Share (%), By Distribution Channel, 2017-2031F
• Figure 8. Vietnam Generic Drugs Market Share (%), By Region, 2017-2031F
• Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 11. By Brand Size Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023